Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Hexaminolevulinate Photodynamic Therapy (HAL-PDT) With Deferred Surgery Versus Surgery for High-grade Squamous Intraepithelial Lesions (HSIL) (Aurora)

8. juli 2026 oppdatert av: Lu Huaiwu, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

A Prospective, Open-label, Randomized, Controlled, Non-inferiority Phase II Study Comparing HAL-PDT With Deferred Surgery Versus Immediate Surgery in Subjects With High-grade Squamous Intraepithelial Lesions (HSIL)

High-grade squamous intraepithelial lesions (HSIL), encompassing cervical intraepithelial neoplasia grade 2 (CIN2) with p16 positivity and grade 3 (CIN3), are precancerous conditions that require effective intervention. This Phase II study aims to comprehensively evaluate the efficacy, safety, and impact on quality of life of hexaminolevulinate photodynamic therapy (HAL-PDT) with deferred surgery compared to immediate surgical treatment in subjects with HSIL.

This is a prospective, open-label, randomized, controlled, non-inferiority trial. A total of 230 subjects are planned to be enrolled, with 115 subjects allocated to each treatment group (HAL-PDT with Deferred Surgery or Immediate Surgery ).

The primary endpoint is the pathological regression rate at 12 months, defined as histological findings of normal tissue or low-grade squamous intraepithelial lesions (LSIL) via colposcopy-directed biopsy. Key secondary endpoints include Human Papillomavirus (HPV) clearance rates at 6 and 12 months, pathological regression rate at 6 months, quality of life assessed by the EORTC QLQ-CX24 questionnaire, safety profiles (incidence, severity, and duration of AEs and SAEs, as well as their relationship to the study treatments), and the proportion of subjects developing cervical cancer within 12 months.

Studieoversikt

Detaljert beskrivelse

High-grade squamous intraepithelial lesions (HSIL), encompassing cervical intraepithelial neoplasia grade 2 (CIN2) with p16 positivity and grade 3 (CIN3), are well-established precursors to invasive cervical cancer. Immediate excisional procedures such as loop electrosurgical excision procedure (LEEP) or cold knife conization remain the standard of care; however, they are associated with significant long-term morbidities, including cervical stenosis, cervical incompetence, and adverse obstetric outcomes in women of childbearing age. Hexaminolevulinate photodynamic therapy (HAL-PDT) is a non-invasive, tissue-preserving modality that offers a potential alternative.

This Phase II trial is designed to test the hypothesis that HAL-PDT (HAL-PDT Q2W×6 ) with deferred surgery achieves a 12-month pathological regression rate non-inferior to that of immediate surgery, while providing a favorable safety and quality-of-life profile.

A total of 230 subjects are planned for enrollment, with 115 allocated to each treatment arm. The primary efficacy analysis will be performed on both the Intention-to-Treat (ITT) and Per-Protocol (PP) populations to test the non-inferiority margin, which is pre-specified based on clinically acceptable thresholds. Safety analyses will be conducted on the Safety Set (SS).

Studietype

Intervensjonell

Registrering (Antatt)

230

Fase

  • Fase 2

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • Fujian
      • Fuzhou, Fujian, Kina, 350001
        • Fujian Medical University Union Hospital
        • Ta kontakt med:
          • Ethics Committee Administrator
          • Telefonnummer: 0591-83357896
          • E-post: fjxhe_irb@163.com
        • Hovedetterforsker:
          • Dezhao Chen, MD, PhD
      • Fuzhou, Fujian, Kina, 350005
        • The First Affiliated Hospital of Fujian Medical University
        • Ta kontakt med:
          • Ethics Committee Administrator
          • Telefonnummer: 0591-87982001
          • E-post: fdyy_irb@163.com
        • Hovedetterforsker:
          • Lihong Chen, MD, PhD
      • Xiamen, Fujian, Kina, 361001
        • Xiamen Maternity and Child Healthcare Hospital
        • Ta kontakt med:
          • Ethics Committee Administrator
          • Telefonnummer: 0592-2662920
          • E-post: xmfyllwyh@163.com
        • Hovedetterforsker:
          • Qing Li, MD, PHD
      • Xiamen, Fujian, Kina, 361003
        • he First Affiliated Hospital of Xiamen University
        • Ta kontakt med:
        • Hovedetterforsker:
          • Qionghua Chen, MD, PHD
    • Guangdong
      • Foshan, Guangdong, Kina, 528000
        • The First People's Hospital of Foshan
        • Ta kontakt med:
        • Hovedetterforsker:
          • Lijiang Xu, MD, PHD
      • Foshan, Guangdong, Kina, 528300
        • Foshan Shunde Maternal and Child Health Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • Jinzhi Huang, MD, PHD
      • Guangzhou, Guangdong, Kina, 510280
        • Zhujiang Hospital, Southern Medical University
        • Ta kontakt med:
          • Ethics Office Administrator
          • Telefonnummer: +86-020-62783372
          • E-post: zjyygcp@163.com
        • Hovedetterforsker:
          • Xuefeng Wang, MD, PhD
      • Guangzhou, Guangdong, Kina, 510010
        • Guangdong Women and Children Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • Xiaoli Sun, MD, PHD
      • Guangzhou, Guangdong, Kina, 510095
        • The Affiliated Cancer Hospital of Guangzhou Medical University
        • Ta kontakt med:
        • Hovedetterforsker:
          • Bin Wen, MD, PhD
      • Guangzhou, Guangdong, Kina, 510120
        • Guangdong ProvincialHospital of Chinese Medicine
        • Ta kontakt med:
          • Administrator Ethics Committee
          • Telefonnummer: 020-81887233-35943
          • E-post: Ilbgs@gzucm.edu.cn
        • Hovedetterforsker:
          • Jing Xiao, MD, PhD
      • Guangzhou, Guangdong, Kina, 510180
        • Guangzhou First People's Hospital (The Second Affiliated Hospital of South China University of Technology)
        • Ta kontakt med:
          • Ethics Committee Administrator
          • Telefonnummer: 020-81045412
          • E-post: MEC_GZSY@126.com
        • Hovedetterforsker:
          • Yan Kuang, MD, PhD
      • Guangzhou, Guangdong, Kina, 510317
        • Guangdong Second Provincial GeneralHospital (Guangdong Provincial Emergency Hospital)
        • Ta kontakt med:
          • Administrator Clinical Research Office
          • Telefonnummer: +86-20-89168338
          • E-post: gdech_irb@163.com
        • Hovedetterforsker:
          • Xiafei Fu, MD, PhD
      • Guangzhou, Guangdong, Kina, 510405
        • The First AffiliatedHospital, Guangzhou University ofTraditional Chinese Medicine
        • Ta kontakt med:
          • Ethics Committee Administrator
          • Telefonnummer: +86-20-36588667
          • E-post: gztcmlunli@163.com
        • Hovedetterforsker:
          • Sijin Li, MD, PhD
      • Guangzhou, Guangdong, Kina, 510623
        • Guangzhou Women and Children's Medical Center (The Affiliated Women and Children's Medical Center of Guangzhou Medical University)
        • Ta kontakt med:
          • Ethics Committee Administrator
          • Telefonnummer: 020-81886332
          • E-post: gzwc_irb@163.com
        • Hovedetterforsker:
          • Kun Shi, MD, PhD
      • Guangzhou, Guangdong, Kina, 511400
        • Panyu Central Hospital Affiliated to Guangzhou Medical University
        • Ta kontakt med:
        • Hovedetterforsker:
          • Xiang Yang, MD, PhD
      • Shenzhen, Guangdong, Kina, 518036
        • Peking University Shenzhen Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • Zhihong Liu, MD, PhD
      • Shenzhen, Guangdong, Kina, 518031
        • Shenzhen Maternity and Child Health Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • Ping Jin, MD, PHD
      • Zhongshan, Guangdong, Kina, 510080
        • The First Affiliated Hospital, Sun Yat-sen University
        • Ta kontakt med:
        • Hovedetterforsker:
          • Mian He, MD, PHD
        • Hovedetterforsker:
          • Junxiu Liu, MD, PHD
    • Guangxi
      • Nanning, Guangxi, Kina, 530021
        • The First Affiliated Hospital of Guangxi Medical University
        • Ta kontakt med:
        • Hovedetterforsker:
          • Jiangtao Fan, MD, PhD
      • Nanning, Guangxi, Kina, 530000
        • Guangxi Zhuang Autonomous Region Maternal and Child Health Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • Chunqiu Xiong, MD, PHD
    • Guangzhou
      • Dongguan, Guangzhou, Kina, 523000
        • Dongguan Maternal and Child Health Care Hosptial
        • Ta kontakt med:
        • Hovedetterforsker:
          • Ping Zhou, MD, PHD
    • Henan
      • Zhengzhou, Henan, Kina, 450052
        • The First Affiliated Hospital of Zhengzhou University
        • Ta kontakt med:
          • Ethics Committee Administrator
          • Telefonnummer: 0371-66278510
          • E-post: zdyyllwy@163.com
        • Hovedetterforsker:
          • Liping Han, MD, PhD
    • Jiangsu
      • Nanjing, Jiangsu, Kina, 210029
        • The First Affiliated Hospital with Nanjing Medical University (Jiangsu Provincial People's Hospital)
        • Ta kontakt med:
          • Ethics Committee Administrator
          • Telefonnummer: 025-68136360
          • E-post: jsphkj@163.com
        • Hovedetterforsker:
          • Xiaoling Ma, MD, PhD
    • Jinlin
      • Changchun, Jinlin, Kina
        • The First Hospital of Jilin University
        • Ta kontakt med:
        • Hovedetterforsker:
          • Songling Zhang, MD, PHD
    • Liaoning
      • Shenyang, Liaoning, Kina, 110016
        • The General Hospital of Northern Theater Command of the Chinese People's Liberation Army
        • Ta kontakt med:
        • Hovedetterforsker:
          • Lipeng Pei, MD, PhD
    • Shanxi
      • Taiyuan, Shanxi, Kina, 030000
        • Shanxi Provincial People's Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • Yuping Suo, MD, PHD
    • Sichuan
      • Chengdu, Sichuan, Kina, 610041
        • The West China Second University Hospital of Sichuan University
        • Ta kontakt med:
        • Hovedetterforsker:
          • Yuedong He, MD, PHD
    • Zhejiang
      • Hangzhou, Zhejiang, Kina, 310022
        • Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital)
        • Ta kontakt med:
        • Hovedetterforsker:
          • Yichen Wang, MD, PhD

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

  • Barn
  • Voksen
  • Eldre voksen

Tar imot friske frivillige

Nei

Beskrivelse

Inclusion Criteria:

  • Voluntarily participate in this clinical study, fully understand the study content, procedures, and potential adverse reactions, and be able to sign the written informed consent form.
  • Able to complete the study in accordance with the study protocol.
  • Subject age ≥18 years.
  • Presence of High-Grade Squamous Intraepithelial Lesion (HSIL) (CIN2 P16 positive/CIN3), specifically: HSIL with histopathological diagnosis of grade II/III (CIN2 P16 positive/CIN3) within 3 months prior to the first treatment.
  • Adequate colposcopy, including: (a) Complete visibility of the cervical transformation zone, including the squamocolumnar junction; (b) Complete visibility of lesion margins.
  • The investigator determines that non-surgical treatment is acceptable for the participant.
  • The investigator determines that the cervical size is suitable for placement of the HAL-PDT device.
  • Meets the following conditions: Women of childbearing potential (WOCBP) must have a negative serum pregnancy test result prior to the start of treatment. No plan for pregnancy during the study period; no sexual activity or use of effective and reliable contraception from the end of the last menstrual period to the start of the study, and agreement to use condoms for barrier contraception during the study period. WOCBP is defined as a female who has experienced menarche, has not undergone hysterectomy or bilateral oophorectomy, and has not reached natural menopause (i.e., no menstruation at all for the past 24 consecutive months).

Exclusion Criteria:

  • Cervical adenocarcinoma in situ or other glandular lesions, invasive cervical cancer, or suspected malignant lesions.
  • CIN2 with P16 negative.
  • Lesions extending to the vaginal wall, cervical canal, or vaginal fornix, or lesions located on the vulva.
  • Prior physical or surgical treatment to the cervix resulting in incomplete cervical structure (e.g., cold knife conization), or receipt of physical or surgical therapy for CIN2 or CIN3 after the current histopathological diagnosis.
  • The first study treatment day falls within 7 half-lives of the last antiviral medication.
  • Severe pelvic inflammatory disease, severe cervicitis, or other severe gynecological infectious diseases found on colposcopic or clinical examination.
  • Investigator judges that vaginal bleeding during treatment may affect treatment outcomes.
  • Receipt of any inactivated vaccine within 2 weeks prior to the first treatment, or any live vaccine within 4 weeks prior to the first treatment.
  • Previous severe cardiovascular, cerebrovascular, neurological, psychiatric, endocrine, or hematopoietic disease that has not been cured; known severely compromised immune function, or need for long-term use of corticosteroids or immunosuppressants; history of malignancy within 5 years.
  • History of clinically significant immunosuppression or confirmed autoimmune disease; or primary immunodeficiency.
  • Known or newly identified active sexually transmitted diseases (STDs), including but not limited to HIV, syphilis, genital herpes, unless adequately treated and tested negative before study treatment.
  • Presence of a cardiac pacemaker.
  • Suspected or known porphyria, or known allergy to the study drug, its chemically similar compounds, or photosensitizers.
  • Allergy to silicone.
  • Pregnant or breastfeeding women.
  • Delivery or miscarriage within 6 weeks prior to enrollment.
  • Participation in any other clinical trial within 30 days prior to study treatment.
  • Poor compliance or judged by the investigator to be unsuitable for participation in this clinical study.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Hexaminolevulinate Photodynamic Therapy (HAL-PDT) with Deferred Surgery
Subjects receive Hexaminolevulinate Photodynamic Therapy (HAL-PDT) once every 2 weeks (Q2W) for a total of 6 treatment sessions. At 6 months after the first treatment, participants undergo colposcopy-directed cervical biopsy and HPV testing to assess treatment response. Those who achieve pathological remission (normal or LSIL) enter follow-up without surgery. Those who do not achieve remission (persistent HSIL or disease progression) receive standard surgical treatment (LEEP or CKC) within 4 weeks of the 6-month assessment.
HAL-PDT is a drug-device combination product. The drug is hexaminolevulinate hydrochloride (HAL) 5% ointment. The device is a single-use cervical light delivery device (CL7) with integrated red LEDs. The ointment is applied into the device cup, placed against the cervix for 5 hours of drug absorption, then automatically delivers 125 J/cm² photodynamic therapy for 4 hours and 36 minutes. Total in-situ time is 11-24 hours. Patients remove the device themselves. Treatment regimen: one session every 2 weeks for a total of 6 sessions (Q2W × 6).
Aktiv komparator: Immediate Surgery
Participants with histologically confirmed HSIL (CIN2 P16 positive/CIN3) receive standard surgical treatment (LEEP or CKC) per routine clinical practice. Follow-up assessments include HPV testing and colposcopy-directed cervical biopsy at 6 months and 12 months post-surgery to evaluate pathological remission and HPV clearance rates. Safety monitoring is conducted from signing of informed consent through the end of study.
Subjects undergo immediate surgical excision of the cervical lesion via either Loop Electrosurgical Excision Procedure (LEEP) or Cold Knife Conization (CKC), as determined by the investigator based on the subject's individual lesion characteristics, size, and clinical presentation, following standard institutional surgical protocols.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Histopathological regression rate at 12 months
Tidsramme: 12 months after the first treatment
Proportion of participants with pathological remission on colposcopy-directed cervical biopsy at 12 months after the first treatment. Pathological remission is defined as histopathological finding of normal tissue or low-grade squamous intraepithelial lesion (LSIL)
12 months after the first treatment

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Pathological remission rate at 6 months
Tidsramme: 6 months after the first treatment
Proportion of participants with pathological remission on colposcopy-directed cervical biopsy at 6 months after the first treatment. Pathological remission is defined as histopathological finding of normal tissue or low-grade squamous intraepithelial lesion (LSIL).
6 months after the first treatment
HPV baseline clearance rate at 12 months
Tidsramme: 12 months after the first treatment
Proportion of participants with clearance of baseline high-risk HPV subtypes at 12 months after the first treatment. HPV clearance is defined as undetectable of the same high-risk HPV subtype(s) that were present at baseline.
12 months after the first treatment
Incidence of cervical cancer at 12 months
Tidsramme: 12 months after the first treatment
Proportion of participants with histologically confirmed cervical cancer (any stage) diagnosed within 12 months after the first treatment.
12 months after the first treatment
Human Papillomavirus (HPV) baseline clearance rate at 6 months
Tidsramme: 6 months after the first treatment
Proportion of participants with clearance of baseline high-risk Human Papillomavirus (HPV) subtypes at 6 months after the first treatment. HPV clearance is defined as undetectable of the same high-risk HPV subtype(s) that were present at baseline.
6 months after the first treatment
Quality of life assessed by EORTC QLQ-CX24
Tidsramme: 12 months after the first treatment
Quality of life assessed by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Cervical Cancer Module (EORTC QLQ-CX24). Scores for each domain are linearly transformed to a 0-100 scale. For global health status and functional domains, a higher score indicates a better outcome (better quality of life/function). For symptom scales, a higher score indicates a worse outcome (more severe symptoms).
12 months after the first treatment
Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)
Tidsramme: From informed consent through 12 months after the first treatment
Incidence, type, severity (mild, moderate, severe), duration, and relatedness to photodynamic therapy and/or surgical treatment of adverse events (AEs) and serious adverse events (SAEs) occurring from signing of informed consent through the end of study follow-up.
From informed consent through 12 months after the first treatment

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

1. juli 2026

Primær fullføring (Antatt)

16. juni 2029

Studiet fullført (Antatt)

16. juni 2029

Datoer for studieregistrering

Først innsendt

21. juni 2026

Først innsendt som oppfylte QC-kriteriene

21. juni 2026

Først lagt ut (Faktiske)

25. juni 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

9. juli 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

8. juli 2026

Sist bekreftet

1. juli 2026

Mer informasjon

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere